Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries

Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no re...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2015-06, Vol.21 (6), p.977-983
Main Authors: Kurbatova, Ekaterina V, Dalton, Tracy, Ershova, Julia, Tupasi, Thelma, Caoili, Janice Campos, Van Der Walt, Martie, Kvasnovsky, Charlotte, Yagui, Martin, Bayona, Jaime, Contreras, Carmen, Leimane, Vaira, Via, Laura E, Kim, HeeJin, Akksilp, Somsak, Kazennyy, Boris Y, Volchenkov, Grigory V, Jou, Ruwen, Kliiman, Kai, Demikhova, Olga V, Cegielski, J Peter
Format: Article
Language:English
Subjects:
Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries
Analysis
antimicrobial resistance
Antitubercular agents
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
bacteria
Care and treatment
Drug Resistance, Multiple, Bacterial
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - epidemiology
Extensively Drug-Resistant Tuberculosis - microbiology
Humans
Microbial drug resistance
Microbial Sensitivity Tests
multidrug-resistant tuberculosis
Mycobacterium tuberculosis - drug effects
second-line drug resistance
Tuberculosis
tuberculosis and other mycobacterial infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5-6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2-4) drugs; 26% retained susceptibility to
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2106.141329